← boardnext 2026-12next 2028-03-03
ALZN
Alzamend Neuro, Inc.distress 9/10 · high distress / dilution risk$1.31-3%today-63% from 52w high
Lead: Alzheimer Disease · target Sortilin/PGRN · est. market ~$8B (approx, global)
Revenue
pre-revenue
Liquidity
$3M
Runway
0.4 yrs
Shares 1y
+31%
Price & events
-42.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.0%
1D
+7.4%
1W
-4.4%
1M
+15.9%
3M
-40.5%
6M
-56.5%
1Y
-96.1%
2Y
-100.0%
5Y
-100.0%
All
Overview
- Market Cap
- $4.98M
- Volume
- 3.71K
- 52 Week Range
- $0.86 – $3.53
- Total Shares
- 3.80M
- Float Shares
- 3.79M
- Short %
- 4.16%
- % Held by Insiders
- 0.53%
- % Held by Institutions
- 3.04%
- RVOL
- 0.02x
- Beta
- 0.14
Pipeline stages · 2 programs
AL001, Lithium carbonate
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ALZN002 (autologous DCs pulsed with E22W mutant peptide)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2027-01-15 | Phase 1/2 | AL001, Lithium carbonate | Bipolar I Disorder | — | recruiting |
| 2028-03-03 Estimated 50% readout ~2028-04-17 | Phase 1/2 | ALZN002 (autologous DCs pulsed with E22W mutant peptide) | Alzheimer Disease | — | active not recruiting |
| 2025-12 | Phase 1 | AL001, Lithium Carbonate Capsule | Pharmacokinetics, Neurology | 6 | active not recruiting |
Catalyst news & presentations · 1
- 2025trial initiationsecondaryPhase 2AL001 · Five Phase II clinical trials of AL001 in partnership with Massachusetts General Hospital.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-12-22Ascendiant CapitalBuy
- 2025-09-25Ascendiant CapitalBuy
- 2025-08-21Ascendiant CapitalBuy
- 2025-03-17Ascendiant CapitalBuy
- 2024-12-16Ascendiant CapitalBuy
- 2024-11-11Ascendiant CapitalBuy
Competitors — Sortilin/PGRN
- ALECAlector, Inc.$167M · D5
Recent news
- 2026-07-22Alzamend Neuro FY 2026: Revenue $0 EPS $(2.63) — 10-K Summary - TradingView
- 2026-07-21Alzamend Neuro Announces Passing of Board Director - TipRanks
- 2026-07-17Alzamend Neuro Inc expected to post a loss of 67 cents a share - Earnings Preview - TradingView
- 2026-06-3012 Health Care Stocks Moving In Tuesday's After-Market Session - Alzamend Neuro (NASDAQ:ALZN), Vivos Ther - Benzinga
- 2026-06-30ALZN Q4'25 Earnings: EPS estimate is (0.67) USD - TradingView
- 2026-06-26Alzamend Neuro, Inc. Actuals & Estimates (NASDAQ:ALZN) - TradingView
- 2026-06-26Price to book forward of Alzamend Neuro, Inc. – NASDAQ:ALZN - TradingView
- 2026-06-26ALZN Forecast — Price Target — Prediction for 2027 - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.